Acute Respiratory Distress Syndrome (ARDS) and Acute Respiratory Failure (ARF) Following Hematopoietic Stem Cell Transplantation

Overview

Información sobre este estudio

The purpose of this study is to deepen our understanding of the ARDS mechanism following transplantation through an analysis of cytokines, metabolomics and proteomics before ARDS occurs, and during the early phase of ARDS development.

 

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Adult (age 18 or greater) patients who consent for enrollment in the study.
  • Have undergone allogeneic HSCT within 100 days or autologous HSCT within 30 days.

Exclusion Criteria: 

  • Subject transferred from another institution having already been admitted there for > 24h. This proposal seeks to create a biorepository whose purpose will be to determine mechanism of ARF/ARDS development based on initial hospital course. If a substantial part of a patient’s hospital course preceeds enrollment (and is affected by care received at another institution), we may not get meaningful insights into the ARDS mechanism by enrolling them well into the disease processes that are involved in the pathogenesis of ARDS.
  • ARDS at the time of hospital admission. Since this study is looking at the mechanisms of ARDS development, we would seek to enroll patients before ARDS develops. 
  • Patient’s goals of care are such that ICU transfer (and specifically use of noninvasive or mechanical ventilation) would not be considered. As such, these patients would not be able to develop the outcome of interest (ARDS).
  • Admitted for:
    • Admission only for chemotherapy administration;
    • Control of symptoms related to diarrhea, vomiting, dehydration due to inability to swallow, dysphagia, pain or mucositis. 

Eligibility last updated 12/7/22. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Hemang Yadav, M.B.B.S.

Abierto para la inscripción

Contact information:

Hemang Yadav M.B.B.S.

(507) 284-2416

Yadav.Hemang@mayo.edu

Scottsdale/Phoenix, Ariz.

Investigador principal de Mayo Clinic

Rodrigo Cartin-Ceba, M.D.

Abierto para la inscripción

Contact information:

Fady Khorany C.Ph.T.

(480) 574-1323

Khorany.Fady@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20538650

Mayo Clinic Footer